Oruka Therapeutics (FRA:HQ1) Debt-to-Equity : -3.54 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Debt-to-Equity?

Oruka Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Oruka Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €22.98 Mil. Oruka Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €-6.49 Mil. Oruka Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -3.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oruka Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:HQ1's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Oruka Therapeutics Debt-to-Equity Historical Data

The historical data trend for Oruka Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Debt-to-Equity Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Debt-to-Equity

Oruka Therapeutics Semi-Annual Data
	Mar24
Debt-to-Equity	-3.54

Competitive Comparison of Oruka Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Oruka Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Debt-to-Equity falls into.

Oruka Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oruka Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.203	+	0.721)	/	365.021
	=	0.00

Oruka Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	22.982)	/	-6.494
	=	-3.54

Oruka Therapeutics (FRA:HQ1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oruka Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ORKA:USA

Address

221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453

Website

Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.

Oruka Therapeutics Headlines

No Headlines